Long Ideas - Curis (CRIS) has been around for quite some time with little to show for it but a significant long-term loss and some dud product candidates. … Continue Reading
Read NowLong Ideas - Incyte (INCY), which markets Jakafi (ruxolitinib) for the treatment of myelofibrosis, is well positioned for a strong 2nd half of 2013, as a host of … Continue Reading
Read NowLong Ideas - Update: On the morning of July 15th, Curis announced that the European Commission granted the conditional approval of Erivedge (vismodegib) for the treatment of adult patients with … Continue Reading
Read NowRecap - Darapladib failed two mid-stage studies in 2008, yet GlaxoSmithKline (GSK) moved the cardiovascular drug into Phase III trials nonetheless. While most investors consider the large … Continue Reading
Read NowLong Ideas - Ahead of key Phase II data for Ampyra, we believe that shares of Acorda Therapeutics (ACOR) are worth a look. The company will release Phase … Continue Reading
Read NowLong Ideas - With the majority of statins now generic, pharmaceutical companies are on the hunt for the next blockbuster cardiovascular drug to replace what was once a … Continue Reading
Read NowMost Popular - Medivation (MDVN) has made a rapid come-back since investors exited en masse in mid-June as the company’s closest development-stage competitor was bought by J&J (JNJ). … Continue Reading
Read Now